(0.29%) 5 114.66 points
(0.31%) 38 358 points
(0.33%) 15 981 points
(-0.91%) $83.09
(5.77%) $2.03
(0.36%) $2 355.70
(0.44%) $27.66
(4.01%) $959.05
(-0.22%) $0.933
(-0.38%) $10.98
(-0.55%) $0.796
(1.69%) $93.43
@ $2.49
発行日: 14 2月 2024 @ 05:29
リターン: 0.98%
前回のシグナル: 2月 13 - 23:30
前回のシグナル:
リターン: 0.81 %
Live Chart Being Loaded With Signals
Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration...
Stats | |
---|---|
本日の出来高 | 639 116 |
平均出来高 | 2.25M |
時価総額 | 377.97M |
EPS | $0 ( 2024-03-12 ) |
次の収益日 | ( $-0.0900 ) 2024-06-13 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -3.14 |
ATR14 | $0.00500 (0.20%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-19 | Duarte Ira | Buy | 3 874 | Common Stock |
2024-04-19 | Duarte Ira | Sell | 1 122 | Common Stock |
2024-04-19 | Duarte Ira | Sell | 3 874 | Restricted Stock Units |
2024-04-19 | Forbes William P | Buy | 3 874 | Common Stock |
2024-04-19 | Forbes William P | Sell | 3 874 | Restricted Stock Units |
INSIDER POWER |
---|
66.41 |
Last 96 transactions |
Buy: 15 032 989 | Sell: 3 241 807 |
ボリューム 相関
Heron Therapeutics Inc 相関
10 最も正の相関 | |
---|---|
TTGT | 0.894 |
TFFP | 0.891 |
RMRM | 0.888 |
VSTA | 0.884 |
TLGT | 0.881 |
ARVN | 0.881 |
BIOL | 0.88 |
GAINL | 0.875 |
PAIC | 0.875 |
WISA | 0.875 |
10 最も負の相関 | |
---|---|
BOCH | -0.901 |
NETE | -0.9 |
AMRB | -0.894 |
MMAC | -0.888 |
SHSP | -0.886 |
VLYPO | -0.877 |
SEDG | -0.866 |
IBEX | -0.864 |
SLGN | -0.856 |
RNLC | -0.854 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Heron Therapeutics Inc 相関 - 通貨/商品
Heron Therapeutics Inc 財務諸表
Annual | 2023 |
収益: | $127.04M |
総利益: | $61.94M (48.75 %) |
EPS: | $-0.800 |
FY | 2023 |
収益: | $127.04M |
総利益: | $61.94M (48.75 %) |
EPS: | $-0.800 |
FY | 2022 |
収益: | $107.67M |
総利益: | $52.80M (49.04 %) |
EPS: | $-1.240 |
FY | 2021 |
収益: | $87.18M |
総利益: | $41.16M (47.21 %) |
EPS: | $-2.24 |
Financial Reports:
No articles found.
Heron Therapeutics Inc
Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; HTX-019, an investigational agent for the prevention of postoperative nausea and vomiting; and HTX-034 for postoperative pain management, as well as is in Phase Ib/II clinical study in patients undergoing bunionectomy. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。